SAA receives no government funding and relies on the generous donations from individuals to create and maintain the programs and services aimed at improving the futures of the 3.2 million Americans affected by spondyloarthritis.
The biologic drug landscape shifted in March 2015 when The Food and Drug Administration approved the first of a new subclass of treatments to be marketed in the United States—biosimilars. Recently, a second biosimilar product—Inflectra (infliximab-dyyb)—a biologic…
Chloe is an Accredited Practicing Dietitian and Sports Dietitian who specializes in nutrition for arthritis and inflammatory joint disease, food intolerance, and sports...
Input your search keywords and press Enter.
